Stifel analyst Thomas Shrader said he tries "not to respond to speculation, blogs, and the work of other analysts," but in light of today's selloff in shares of Intrexon he reiterated his belief in the company's ability is synthetic biology. Additionally, he said he considers the natural gas to liquid fuels project to be the company's most valuable, said he thinks Intrexon and its partners have "a lot of good ideas and relatively unique abilities to test those ideas" in the area of T-Cells in oncology therapeutics and said he believes OX513A can play a role in fighting Zika virus. Shrader keeps a Buy rating and $57 price target on Intrexon shares, which are down 27% to $26.84 in afternoon trading.